Piper Sandler initiated coverage of Grail (GRAL) with a Neutral rating and $54 price target The company holds the largest clinical datasets of any company in the multi-cancer early detection space, the analyst tells investors in a research note. Piper views Grail as the best pure-play in group but starts the shares at Neutral as it monitors the company’s regulatory and reimbursement pathway.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Grail announces collaboration with Epic to bring Galleri test to EHR platforms
- Grail, Superpower partner to expand early cancer detection
- Grail price target lowered to $75 from $130 at Guggenheim
- Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- Video: Constellation rises as Citi gets more constructive